长期口服β受体阻滞剂对脓毒症心肌损伤及预后的影响
该回顾性研究纳入2015年1月至2020年6月浙江省同德医院EICU和ICU收治的289例脓毒症心肌损伤患者,其中诊断前3个月内未服用β受体阻滞剂者187例为非β受体阻滞剂组,诊断前每日口服β受体阻滞剂超过3个月者102例为β受体阻滞剂组。结果显示β受体阻滞剂组诊断时心率显著低于非β受体阻滞剂组(107±8 vs. 110±7 bpm,P<0.01),诊断24小时内cTnI和BNP显著低于非β受体阻滞剂组(均P<0.05)。但两组MAP、CK-MB、乳酸、ScvO2、SOFA评分、APACHE II评分、LVEF、E/A、血管活性药物使用率和28天病死率均无显著差异(均P>0.05)。作者认为长期口服β受体阻滞剂可减轻脓毒症患者心肌损伤,对病情严重程度和预后无影响。
要点
- β受体阻滞剂组诊断时心率显著低于非β受体阻滞剂组(107±8 vs. 110±7 bpm,P<0.01)。
- β受体阻滞剂组诊断24小时内cTnI和BNP显著低于非β受体阻滞剂组[cTnI:0.191(0.220)vs. 0.291(0.300)μg/L,BNP:627(133)vs. 690(201)ng/L,均P<0.05]。
- 两组MAP、CK-MB、乳酸、ScvO2、SOFA评分、APACHE II评分、LVEF、E/A、血管活性药物使用率和28天病死率均无显著差异(均P>0.05)。
- 28天病死率β受体阻滞剂组23.5%(24/102)vs. 非β受体阻滞剂组25.7%(48/187),差异无统计学意义(P>0.05)。
- 作者认为长期口服β受体阻滞剂可减轻脓毒症患者心肌损伤,对病情严重程度和预后无影响。
适用人群与场景
- 2015年1月至2020年6月浙江省同德医院EICU和ICU收治的符合脓毒症心肌损伤标准的患者,共289例纳入分析。
- 非β受体阻滞剂组:诊断前3个月内从未服用β受体阻滞剂者187例;β受体阻滞剂组:诊断前每日口服β受体阻滞剂超过3个月者102例。
研究设计与关键结果
- 研究类型:回顾性研究;样本量289例;人群:浙江省同德医院EICU和ICU收治的脓毒症心肌损伤患者;分组:非β受体阻滞剂组187例(诊断前3个月内未服用β受体阻滞剂)vs. β受体阻滞剂组102例(诊断前每日口服β受体阻滞剂超过3个月)。
- 主要终点:诊断时心率β受体阻滞剂组107±8 bpm vs. 非β受体阻滞剂组110±7 bpm,β受体阻滞剂组显著降低(P<0.01);诊断24小时内cTnI β受体阻滞剂组0.191(0.220)μg/L vs. 非β受体阻滞剂组0.291(0.300)μg/L,BNP β受体阻滞剂组627(133)ng/L vs. 非β受体阻滞剂组690(201)ng/L,均显著降低(均P<0.05)。
- 关键次要终点:MAP β受体阻滞剂组70.6±3.9 mmHg vs. 非β受体阻滞剂组69.9±3.8 mmHg,CK-MB 4.24(3.33)μg/L vs. 4.32(3.13)μg/L,乳酸3.50(1.80)mmol/L vs. 3.50(1.90)mmol/L,ScvO2 0.729±0.032 vs. 0.735±0.041,SOFA评分7.74±2.34 vs. 7.25±2.23,APACHE II评分17.19±5.13 vs. 18.27±6.12,LVEF 0.567±0.058 vs. 0.557±0.051,E/A 0.71(0.20)vs. 0.69(0.20),血管活性药物使用率60.8%(62/102)vs. 56.7%(106/187),28天病死率23.5%(24/102)vs. 25.7%(48/187),两组均无显著差异(均P>0.05)。
证据类型、等级与局限
- 证据类型:回顾性研究;证据等级:原文未给出。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为长期口服β受体阻滞剂可减轻脓毒症患者心肌损伤,对病情严重程度和预后无影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the effect of long-term oral administration of β-blocker on septic myocardial injury and prognosis.
METHODS: A retrospective study was conducted. Patients who were admitted to the emergency intensive care unit (EICU) and intensive care unit (ICU) of Tongde Hospital of Zhejiang Province from January 2015 to June 2020 were enrolled. A total of 289 patients who met the criteria of myocardial injury induced by sepsis were included in the analysis. Among them, 187 patients who had never taken β-blocker within 3 months before diagnosis were divided in the non-β-blocker group, and 102 patients who took β-blocker daily for more than 3 months before diagnosis were in the β-blocker group. The physiological and biochemical characteristics were compared between the two groups, including heart rate, mean arterial pressure (MAP) at the time of diagnosis, cardiac troponin I (cTnI), brain natriuretic peptide (BNP), MB isoenzyme of creatine kinase (CK-MB), blood lactic acid (Lac), central venous oxygen saturation (ScvO2), sequential organ failure assessment (SOFA) score, acute physiology and chronic health evaluation II (APACHE II) score within 24 hours of diagnosis, left ventricular ejection fraction (LVEF), early and late mitral orifice diastolic peak flow velocity ratio (E/A), utilization rate of vasoactive drugs during hospitalization and 28-day mortality.
RESULTS: The heart rate in the β-blocker group at the time of diagnosis was significantly lower than that in the non-β-blocker group (bpm: 107±8 vs. 110±7, P < 0.01), and the levels of cTnI and BNP within 24 hours of diagnosis were significantly lower than those in the non-β-blocker group [cTnI (μg/L): 0.191 (0.220) vs. 0.291 (0.300), BNP (ng/L): 627 (133) vs. 690 (201), both P < 0.05]. However, there were no significant differences in MAP, CK-MB, Lac, ScvO2, SOFA score, APACHE II score, LVEF, E/A, vasoactive drug utilization rate, and 28-day mortality between the β-blocker and non-β-blocker groups [MAP (mmHg, 1 mmHg = 0.133 kPa): 70.6±3.9 vs. 69.9±3.8, CK-MB (μg/L): 4.24 (3.33) vs. 4.32 (3.13), Lac (mmol/L): 3.50 (1.80) vs. 3.50 (1.90), ScvO2: 0.729±0.032 vs. 0.735±0.041, SOFA score: 7.74±2.34 vs. 7.25±2.23, APACHE II score: 17.19±5.13 vs. 18.27±6.12, LVEF: 0.567±0.058 vs. 0.557±0.051, E/A: 0.71 (0.20) vs. 0.69 (0.20), vasoactive drug utilization rate: 60.8% (62/102) vs. 56.7% (106/187), 28-day mortality: 23.5% (24/102) vs. 25.7% (48/187), all P > 0.05].
CONCLUSIONS: Long-term oral administration of β-blocker reduce myocardial injury in septic patients, and has no effect on disease severity and prognosis.
参考来源
- Yang C, Yu D, Chang C, et al. [Effects of long-term oral administration of β-blocker on septic myocardial injury and prognosis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2021. PMID: 34955132. doi:10.3760/cma.j.cn121430-20201217-00761
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。